Revolution Medicines presented data from the Phase 3 RASolute 302 trial showing that RASONQUE (daraxonrasib) significantly improves overall survival compared to chemotherapy in previously treated metastatic pancreatic cancer patients across various genetic subgroups, including those without identified RAS mutations. The drug demonstrated consistent benefits across different chemotherapy regimens and prior treatment settings, reinforcing its potential as a new standard of care. RASONQUE is already approved in the U.S. and is under regulatory review in Europe and other regions, with ongoing trials to expand its use in RAS-driven cancers.
Revolution Medicines Inc. has a market cap of $40.22 billion and an enterprise value of $36.93 billion as of Oct 23, 2026, 18:41 WIB. On Pluang, its stock price is USD 186.70, down 0.61% for the day, with a trading volume of 1,487,129 shares. This trading activity reflects ongoing investor interest as the company presents promising clinical data for RASONQUE in metastatic pancreatic cancer.
Revolution Medicines, a commercial-stage oncology company focused on RAS-addicted cancers, will announce its financial results for the third quarter of 2026 on November 4, 2026, after market close. The company will host a webcast at 4:30 p.m. ET to d...
Revolution Medicines has initiated treatment in its global Phase 3 RASolve 308 trial, testing zoldonrasib combined with pembrolizumab and chemotherapy as a first-line therapy for metastatic RAS G12D non-squamous non-small cell lung cancer (NSCLC). Th...
